TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07554222: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participan

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 160 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,614,080

Rescue Site Savings

+$3,701,784

Unlock Full NCT07554222 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07554222 Rescue Dossier →